Gastrointestinal complications of transplant immunosuppression

Journal of the American Society of Nephrology

Volumn 13, Issue 1, 2002, Pages 277-287

  Helderman, J H ^a   Goral, S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZATHIOPRINE; CLOTRIMAZOLE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; FLUCONAZOLE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; IVERMECTIN; LANSOPRAZOLE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; NYSTATIN; OMEPRAZOLE; PREDNISONE; RANITIDINE; STEROID; TACROLIMUS; TIABENDAZOLE; UNINDEXED DRUG; VANCOMYCIN;

BILIARY TRACT DISEASE; DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DIVERTICULOSIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; PANCREATITIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

EID: 0036138550     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. A comparison of FK506 (FK506) and CsA for immunosuppression after cadaveric renal transplantation
2. A comparison of FK506 (FK506) and CsA for immunosuppression in liver transplantation
3. Giant gastric ulcers and risk factors for gastroduodenal mucosal disease in orthotopic lung transplant patients
4. Gastroenterologic considerations of organ transplantation
5. Incidence, complications, treatment, and outcome of ulcers of the upper GI tract after renal transplantation during the CsA era
6. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
7. Cytomegalovirus infection of the upper GI tract following liver transplantation - Incidence, location, and severity in CsA- and FK506-treated patients
8. GI surgical emergencies following kidney transplantation
9. CMV allograft pancreatitis: Diagnosis, treatment, and histological features
10. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients
11. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
12. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
13. Mycophenolate mofetil for the treatment of refractory, acute cellular renal transplant rejection
14. Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain
15. Is cytomegalovirus infection related to mycophenolate mofetil after kidney transplantation? A case-control study
16. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group
17. Cytomegalovirus prophylaxis in solid organ transplant recipients
18. Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients
19. Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: Is it effective?
20. Prophylaxis against herpes infections in kidney transplant patients with special emphasis on CMV
21. Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver transplantation database
22. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients
23. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients
24. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients
25. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
26. Herpes simplex esophagitis after renal transplantation
27. Infection in solid-organ transplant recipients
28. Tracheoesophageal fistula: A serious complication of infectious esophagitis
29. Evidence for an increased rate of bacterial infection in liver transplant patients with cytomegalovirus infection
30. Prophylactic fluconazole in liver transplant recipients: A randomized, double-blind, placebo-controlled trial
31. Prophylactic fluconazole in liver transplant recipients: A randomized, double-blind, placebo-controlled trial
32. Yersinia enterocolitica septicemia in a renal transplant recipient on oral iron supplementation
33. Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation
34. Clostridium difficile colitis after kidney and kidney-pancreas transplantation
35. Microsporidia infection in transplant patients
36. Opportunistic infections with Strongyloides stercoralis in renal transplantation
37. Strongyloides hyperinfection in a renal transplant recipient receiving cyclosporine: Possible Strongyloides stercoralis transmission by kidney transplant
38. Disseminated strongyloidiasis complicating acute renal allograft rejection. Prolonged thiabendazole administration and successful retransplantation
39. Helicobacter pylori infection in haemodialysis patients and renal transplant recipients
40. Helicobacter pylori in renal transplant recipients
41. Histologically diagnosed Helicobacter pylori in heart transplant recipients
42. GI toxicity associated with FK 506 in liver transplant recipients
43. Mycophenolate mofetil in cadaveric renal transplantation
44. Histolological morphology of colitis associated with mycophenolate mofetil (MMF) in renal allograft recipients: Acute graft versus host disease (GVH)-like features
45. Mycophenolate mofetil-induced villous atrophy
46. Sirolimus: A new agent for prevention of renal allograft rejection
47. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients
48. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
49. Incidence and management of mycophenolate mofetil adverse effects in simultaneous kidney/pancreas transplant recipients
50. The influence of immunosuppression on peptic ulceration following renal transplantation and the role of endoscopy
51. Corticosteroids and peptic ulcer: Metaanalysis of adverse events during steroid therapy
52. Colonic perforations after renal transplantation
53. GI bleeding after liver transplantation
54. Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients
55. Prophylaxis of acute gastroduodenal bleeding after renal transplantation
56. Prevention of posttransplant peptic ulcer by misoprostol
57. Simultaneous laparotomy and endoscopy for control of bleeding gastric ulcerations after liver transplantation without enterotomy
58. Diverticular disease of the colon: A risk factor for peritonitis in continuous peritoneal dialysis
59. Complicated diverticulitis following renal transplantation
60. Increased incidence of gastrointestinal surgical complications in renal transplant recipients with polycystic kidney disease
61. Colonic screening prior to renal transplantation and its impact on post-transplant colonic complications
62. Acute perforation of the colon associated with chronic corticosteroid therapy
63. Major abdominal complications following cardiac transplantation. Utah Transplantation Affiliated Hospitals Cardiac Transplant Program
64. Colonic ulceration - A previously unreported adverse effect of mycophenolate mofetil
65. Gastric perforation due to mucormycosis after heart-lung and heart transplantation
66. Management of biliary tract disease in heart and lung transplant patients
67. Heart transplantation is associated with an increased risk for pancreaticobiliary disease
68. Cholestasis after cyclosporine A and glucose administration; beneficial effect of canrenoate (soldactone)
69. Cyclosporine A hepatotoxicity: Effect of prolonged treatment with cyclosporine on biliary lipid secretion in the rat
70. Hepatobiliary and pancreatic complications of cyclosporine therapy in 466 renal transplant recipients
71. Acute pancreatitis after liver transplantation: Incidence and contributing factors
72. Pancreatitis in adult orthotopic liver allograft recipients: Risk factors and outcome
73. Management of severe pancreatitis in renal transplant recipients
74. Acute pancreatitis after renal transplantation
75. Acute pancreatitis after cardiac transplantation and other cardiac procedures: Case-control analysis in 24,631 patients
76. Effect of different immunosuppressive agents on acute pancreatitis: A comparative study in an improved animal model
77. Drug-associated acute pancreatitis: Twenty-one years of spontaneous reporting in the Netherlands
78. Incidence of gastrointestinal complications following renal transplantation in the cyclosporin era
79. Malignant disease in patients with long-term renal transplants
80. Malignancies after renal transplantation: The EDTA-ERA registry experience
81. Reduced incidence of rectal cancer, compared to gastric and colonic cancer, in a population of 73,076 men and women chronically immunosuppressed
82. Risk factors for cancer in renal transplant recipients
83. Increased cancer risk after liver transplantation: A population-based study
84. Colon carcinoma in patients undergoing liver transplantation
85. Elationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation
86. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of epstein-barr virus infection in children following liver transplantation
87. Posttransplantation lymphoproliferative disorder: Endoscopic findings
88. Mucosa-associated lymphoid tissue-type lymphomas occurring in post-transplantation patients